SCHEMBL17743971

SCHEMBL17743971

COc1cccc(CCC(=O)O)c1F

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.49
LMNA P02545 1/20 0.49
FFAR4 Q5NUL3 4/20 0.47
FFAR1 O14842 4/20 0.47
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
PPARA Q07869 1/20 0.44
LTB4R Q15722 1/20 0.44
LTB4R2 Q9NPC1 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KMT2A Q03164 1/20 0.43
ALKBH1 Q13686 1/20 0.43
PTGER1 P34995 1/20 0.42
PTGER4 P35408 1/20 0.42
PTGER3 P43115 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31114215 0.89 PPARA (0.51) LMNAFFAR4PPARALTB4RLTB4R2
SCHEMBL6112752 0.89 PPARA (0.51) LMNAFFAR4PPARALTB4RLTB4R2
SCHEMBL27828872 0.85 POLB (0.54) POLBLMNAFFAR4FFAR1
SCHEMBL28295331 0.84 KMT2A (0.41) CA12CA1CA2CA7CA9
SCHEMBL3234088 0.83 CXCL8 (0.53) POLBLMNACA12CA1CA2
SCHEMBL362209 0.83 LMNA (0.59) POLBLMNAFFAR1NPSR1SMN1; SMN2
SCHEMBL29590071 0.83 LMNA (0.59) POLBLMNAFFAR1NPSR1SMN1; SMN2
SCHEMBL3691207 0.82 ALOX5 (0.59) POLBLMNAFFAR1CA12CA1
SCHEMBL490691 0.82 CTSG (0.56) LMNAFFAR4CA12CA1CA2
SCHEMBL3954801 0.82 LMNA (0.50) POLBLMNAFFAR4FFAR1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3020717-B1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO (JP) 2021-12-15 EP disclosed
US-9873683-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2018-01-23 US disclosed
US-9840497-B2 2017-12-12 US disclosed
US-20160244434-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD. (JP) 2016-08-25 US disclosed
EP-3020717-A1 P2X4 RECEPTOR ANTAGONIST Nippon Chemiphar Co., Ltd. (JP) 2016-05-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244434-A1 P2X4 RECEPTOR ANTAGONIST P2RX1, P2RX7, P2RX2 POLB 4442/4885LMNA 1239/4885FFAR4 561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.